Of course, let’s not kid ourselves: vaccine approvals and the clear US elections outcome do not imply a straightforward path ahead. First, the distribution of vaccines has had a slow start in most countries. Second, the win of the two Georgia Senate seats on 5 January 2021 has secured a 50-50 tie between the Democratic and the Republican parties, implying a de facto ‘blue’ majority, given the tie-break vote of Vice President Harris.
Yet, this does not offer free reign to the Biden administration on all of its planned policies as the administration’s legislative proposals could be blocked in the Senate by filibuster, which can only be overcome with a 60-strong majority or in the budget reconciliation process.
While we recognize the hurdles ahead, we believe that neither of the two issues, the slower vaccinations and the prospect of potential filibuster, are reasons enough to change our supportive stance on global equities. They could, however, cause the occasional negative market reaction. As we have maintained for the last few quarters, the Covid-19 outbreak and its impact on the economic recovery remain the key drivers behind equity markets.
But the amount of resources put in by governments and the healthcare community to increase the vaccination rates worldwide is unprecedented. This bodes well for rapid improvement, although certainly not at light speed. The biggest risk, at this point, is the emergence of vaccine-resistant new strains of the virus. Thus far, this does not appear to be the case.
Both our Developed Markets and Emerging Markets teams have turned more positive on their respective equity markets and upgraded their five-factor outlook from neutral to positive. The common denominator is the upgrade of the earnings factor, as earnings revisions have significantly improved across developed and emerging markets and are now positive in both regions.
Importantly, the earnings recovery appears broad based, as earnings revisions are improving across most sectors. As vaccinations and better therapies help mitigate the extent of the Covid-driven economic lockdown, and activity continues to normalize, we expect further rotation from the Covid-beneficiary and Covid-defensive countries and stocks, toward countries and stocks that will benefit from the economic normalization.
Overall, from a regional perspective we continue to favor emerging markets, which is our largest overweight position in our Global portfolios, followed by Europe. We find a few interesting opportunities in Japan, particularly in the technology sector. Within emerging markets, we continue to favor North Asia (China, Taiwan and South Korea).
From a sector standpoint, our largest global overweight position is in technology, although we have cut further our positioning in the tech savvy high flyers in the US and Asia, as comparison bases are destined to become more challenging in the next two quarters and regulatory scrutiny is here to stay. We have also taken additional profit from the Communications Services sector.
We find more opportunities in Industrials, Consumer Discretionary, Specialty Materials and Healthcare, and have selectively added to Financials in the US and in emerging markets. Last but not least, we continue to like sustainability as a theme. Besides the European ‘Green Deal’ and an increasing number of Asian markets pledging carbon neutrality by 2050-2060, the Biden administration with a united Congress should also trigger more investment in this area in the US.
This report is not available for users from countries where the offering of foreign financial services is not permitted, such as US Persons.
Your details are not shared with third parties. This information is exclusively intended for professional investors. All requests are checked.
Please read this important information before proceeding further. It contains legal and regulatory notices relevant to the information contained on this website.
The information contained in the Website is NOT FOR RETAIL CLIENTS - The information contained in the Website is solely intended for professional investors, defined as investors which (1) qualify as professional clients within the meaning of the Markets in Financial Instruments Directive (MiFID), (2) have requested to be treated as professional clients within the meaning of the MiFID or (3) are authorized to receive such information under any other applicable laws. The value of the investments may fluctuate. Past performance is no guarantee of future results. Investors may not get back the amount originally invested. Neither Robeco Institutional Asset Management B.V. nor any of its affiliates guarantees the performance or the future returns of any investments. If the currency in which the past performance is displayed differs from the currency of the country in which you reside, then you should be aware that due to exchange rate fluctuations the performance shown may increase or decrease if converted into your local currency.
In the UK, Robeco Institutional Asset Management B.V. (“ROBECO”) only markets its funds to institutional clients and professional investors. Private investors seeking information about ROBECO should visit our corporate website www.robeco.com or contact their financial adviser. ROBECO will not be liable for any damages or losses suffered by private investors accessing these areas.
In the UK, ROBECO Funds has marketing approval for the funds listed on this website, all of which are UCITS funds. ROBECO is authorized by the AFM and subject to limited regulation by the Financial Conduct Authority. Details about the extent of our regulation by the Financial Conduct Authority are available from us on request.
Many of the protections provided by the United Kingdom regulatory framework may not apply to investments in ROBECO Funds, including access to the Financial Services Compensation Scheme and the Financial Ombudsman Service. No representation, warranty or undertaking is given as to the accuracy or completeness of the information on this website.
If you are not an institutional client or professional investor you should therefore not proceed. By proceeding please note that we will be treating you as a professional client for regulatory purposes and you agree to be bound by our terms and conditions.